The Efficacy and Safety of Prostatectomy for Castration-Naive Oligometastatic Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

130

Participants

Timeline

Start Date

January 1, 2021

Primary Completion Date

December 1, 2024

Study Completion Date

December 2, 2024

Conditions
ProstatectomyOligometastatic Prostate CancerAbiraterone
Interventions
PROCEDURE

robot assisted laparoscopic prostatectomy + enlarged pelvic lymph node dissection

Robot assisted laparoscopic prostatectomy + enlarged pelvic lymph node dissection will be performed.

DRUG

1.Abiraterone Acetate Tablets

1000mg(4 tablets, 250mg per tablet) daily for 6 cycles

DRUG

Prednisone Acetate Tablets

5 mg oral low dose prednisone taken along with Abiraterone Acetate Tablets

DRUG

Luteinizing Hormone-Releasing Hormone Analog

Hypodermic injection of Luteinizing Hormone-Releasing Hormone Analog every 4 weeks including goserelin, leuprolide, triptorelin ect.

Trial Locations (1)

Unknown

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Nanjing

All Listed Sponsors
collaborator

The Affiliated Hospital of Xuzhou Medical University

OTHER

collaborator

The First People's Hospital of Changzhou

OTHER

collaborator

The First Affiliated Hospital of Soochow University

OTHER

collaborator

Wuxi People's Hospital

OTHER

collaborator

The Affiliated Hospital of Nantong University

UNKNOWN

collaborator

The Affiliated Hospital of Yangzhou University

UNKNOWN

lead

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

OTHER

NCT04992026 - The Efficacy and Safety of Prostatectomy for Castration-Naive Oligometastatic Prostate Cancer | Biotech Hunter | Biotech Hunter